Recently, Endi Biology Technology Hebei Co., Ltd was approved to list on the new OTC market and public transfer.

The note shows, Endi Biology’s revenues from January to June in 2015 is ￥4.184 million, and net profit is ￥-2.02 million. The 2014 and 2013 annual revenues of the company are ￥52.43 million and ￥38.72 million, the net profit is ￥-0.18 million and ￥-465 thousand.

Data shows, Caida Securities is Endi Biology’s host broker. Grandall Law Firm is legal adviser. Pan-China Certified Public Accountants for financial audit.

Endi Biology Technology Hebei Co., Ltd was established in Feb 25, 2011. Main business is agents and sales in medical equipment and supplies and gene detection. And the gene detection is the main direction of future development.